The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Open accessAbstract
Osteoporosis is a skeletal disorder characterized by decreased mass and compromised bone strength predisposing to an increased risk of fractures. Although idiopathic osteoporosis is the most common form of osteoporosis, secondary factors may contribute to the bone loss and increased fracture risk in patients presenting with fragility fractures or osteoporosis. Several medical conditions and medications significantly increase the risk for bone loss and skeletal fragility. This review focuses on some of the common causes of osteoporosis, addressing the underlying mechanisms, diagnostic approach and treatment of low bone mass in the presence of these conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–241 of 241
Christiansen, P. (2001) · PubMed · Cited by 58
Levothyroxine treatment and occurrence of fracture of the hip
Sheppard, M. C., Holder, R., & Franklyn, J. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.3.338 · Cited by 56
Drake, M. T. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2387 · Cited by 54
THERAPY OF ENDOCRINE DISEASE: Treatment of osteogenesis imperfecta in adults
Lindahl, K., Langdahl, B. L., Ljunggren, Ö., & Kindmark, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0017 · Cited by 52
Single‐Point Assessment of Warfarin Use and Risk of Osteoporosis in Elderly Men
Woo, C., Chang, L. L., Ewing, S. K., Bauer, D. C., & for the Osteoporotic Fractures in Men Study Group (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01786.x · Cited by 51
Zoledronic Acid in Osteoporosis Secondary to Mastocytosis
Rossini, M., Zanotti, R., Viapiana, O., Tripi, G., Idolazzi, L., Biondan, M., Orsolini, G., Bonadonna, P., Adami, S., & Gatti, D. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.06.015 · Cited by 50
van Rijn, L. E., Pop, V. J., & Williams, G. R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0769 · Cited by 50
Shea, M. L. O., Garfield, L. D., Teitelbaum, S. L., Civitelli, R., Mulsant, B. H., Reynolds, C. F., Dixon, D. J., Doré, P., & Lenze, E. J. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2170-z · Cited by 48
Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients
Mauro, M., Radovic, V., & Armstrong, D. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/216162 · Cited by 47
Pepe, J., Petrucci, M. T., Mascia, M. L., Piemonte, S., Fassino, V., Romagnoli, E., & Minisola, S. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9145-2 · Cited by 47
Rheumatoid arthritis and incident fracture in women: a case–control study
Brennan-Olsen, S. L., Toomey, L., Kotowicz, M. A., Henry, M. J., Griffiths, H., & Pasco, J. A. (2014) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-15-13 · Cited by 47
Maalouf, N. M., Zhang, S., Drechsler, H., Brown, G., Tebas, P., & Bedimo, R. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1988 · Cited by 47
Mazziotti, G., Chiavistelli, S., & Giustina, A. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.014 · Cited by 46
Thomas, T., Horlait, S., Ringe, J. D., Abelson, A. G., Gold, D. T., Atlan, P., & Lange, J. L. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2060-4 · Cited by 45
Zanotti, S., Smerdel‐Ramoya, A., & CANALIS, E. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.161893 · Cited by 45
Self-citationBone turnover in patients with endogenous Cushing’s syndrome before and after successful treatment
Szappanos, Á., Tõke, J., Lippai, D., Patócs, A., Igaz, P., Szücs, N., Fütő, L., Gláz, E., Rácz, K., & Tóth, M. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0978-y · Cited by 43
Yeo, H., Beck, L. H., Thompson, S. R., Farach‐Carson, M. C., McDonald, J. M., Clemens, T. L., & Zayzafoon, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702435200 · Cited by 43
Valente, L. G. O., Pinheiro, M. M., Castro, C. H. D. M., SILVA, A. E., & Szejnfeld, V. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081652 · Cited by 42
Fountas, A., Andrikoula, M., Giotaki, Z., Limniati, C., Tsakiridou, E. D., Tigas, S. K., & Tsatsoulis, A. A. (2015) · Endocrine Practice · doi:10.4158/ep14410.or · Cited by 41
Kristensen, I. B., Christensen, J. H., Lyng, M., Møller, M. B., Pedersen, L., Rasmussen, L. M., Ditzel, H. J., & Abildgaard, N. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.820288 · Cited by 40
RANK ligand and TNF-α mediate acid-induced bone calcium efflux in vitro
Frick, K. K., Strutz, K. L., & Bushinsky, D. A. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00420.2004 · Cited by 37
Positive Celiac Disease Serology and Reduced Bone Mineral Density in Adult Women
Duerksen, D. R., & Leslie, W. D. (2009) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2010/285036 · Cited by 36
Giusti, A. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0584-8 · Cited by 36
Nuclear Factor of Activated T-cells (NFAT)c2 Inhibits Notch Receptor Signaling in Osteoblasts
Zanotti, S., Smerdel‐Ramoya, A., & CANALIS, E. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340455 · Cited by 35
Self-citationLai, J. C., Shoback, D., Zipperstein, J., Lizaola‐Mayo, B., Tseng, S., & Terrault, N. A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3507-6 · Cited by 35
Novel targets for myeloma bone disease
Roodman, G. D. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.11.1377 · Cited by 35
Osteoporosis and Thyrotropin-Suppressive Therapy: Reduced Effectiveness of Alendronate
Panico, A., Lupoli, G., Fonderico, F., Marciello, F., Martinelli, A., Assante, R., & Lupoli, G. (2009) · Thyroid · doi:10.1089/thy.2008.0428 · Cited by 34
Update on Renal Osteodystrophy: Pathogenesis Clinical Management
Sakhaee, K., & Gonzalez, G. B. (1999) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40516-6 · Cited by 32
Lim, H., Kim, H. J., Hong, S. J., & Kim, S. (2014) · Journal of Bone Metabolism · doi:10.11005/jbm.2014.21.3.195 · Cited by 31
Diederich, S., Quinkler, M. O., Burkhardt, P., Großmann, C., Bähr, V., & Oelkers, W. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.0300s3021.x · Cited by 30
Parthan, A., Kruse, M., Agodoa, I., Silverman, S. L., & ORWOLL, E. S. (2013) · Bone · doi:10.1016/j.bone.2013.11.002 · Cited by 29
The Role of Denosumab for Prevention of Skeletal-Related Complications in Multiple Myeloma
Hageman, K., Patel, K. C., Mace, K., & Cooper, M. R. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r776 · Cited by 28
Kearns, A. E., Northfelt, D., Dueck, A. C., Atherton, P. J., Dakhil, S. R., Rowland, K. M., Fuloria, J., Flynn, P. J., Dentchev, T., & Loprinzi, C. L. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-009-0655-x · Cited by 25
Update on Renal Osteodystrophy: Pathogenesis and Clinical Management
Kaplan, N. M., Palmer, B. F., Sakhaee, K., & Gonzalez, G. B. (1999) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199904000-00008 · Cited by 24
Bone alterations in hepatitis C virus infected patients
Pelazas-González, R., González‐Reimers, E., Valls, M. R. A., Santolaria-Fernández, F. J., López-Prieto, J., González-Díaz, A., Gómez-Sirvent, J. L., & de la Vega-Prieto, M. J. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.09.007 · Cited by 23
Adrenal reserve following treatment of graves’ orbitopathy with intravenous glucocorticoids
Giotaki, Z., Fountas, A., Tsirouki, T., Bargiota, A., Tigas, S., & Tsatsoulis, A. (2015) · Thyroid · doi:10.1089/thy.2014.0533 · Cited by 20
Król, C., Dekkers, O. M., Kroon, H. M. J. A., Rabelink, T. J., van Hoek, B., & Hamdy, N. A. T. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1469 · Cited by 19
Deficiencia de micronutrientes y enfermedad celíaca en pediatría
Gladys Guevara, P., Eduardo Chávez, C., & Castillo‐Durán, C. (2014) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2014.457 · Cited by 12
Pepene, C. E., Crişan, N., & Coman, I. (2011) · Clinical and investigative medicine · doi:10.25011/cim.v34i4.15365 · Cited by 10
Is GH therapy useful to preserve bone mass in transition-phase patients with GH deficiency?
Aimaretti, G., Corneli, G., Rovere, S., Croce, C. G., Ghigo, E., & Massimo, P. (2005) · PubMed · Cited by 10
de Klerk, G., Hegeman, J. H., van der Velde, D., van der Palen, J. A. M., van Bergeijk, L., & ten Duis, H. J. (2013) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151458513501176 · Cited by 8
Cited by
Osteoblast-Osteoclast Communication and Bone Homeostasis
Kim, J.-M., Lin, C., Stavre, Z., Greenblatt, M. B., & Shim, J.-H. (2020) · Cells · doi:10.3390/cells9092073 · Cited by 1,178
Zhong, L., Yao, L., Tower, R. J., Wei, Y., Miao, Z., Park, J., Shrestha, R., Wang, L., Yu, W., Holdreith, N., et al. (2020) · eLife · doi:10.7554/elife.54695 · Cited by 335
Pathophysiology and treatment of osteoporosis: Challenges for clinical practice in older people
Barnsley, J., Buckland, G., Chan, P. E., Ong, A., Ramos, A. S., Baxter, M., Laskou, F., Dennison, E. M., Cooper, C., & Patel, H. P. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01817-y · Cited by 199
Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Factors influencing peak bone mass gain
Zhu, X., & Zheng, H. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0748-y · Cited by 160
Metadata
- Authors
- Mirza, F., & Canalis, E.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09
- Volume
- 173
- Issue
- 3
- Pages
- R131-R151
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2131332344
- Cited by
- 331
- References
- 241
- FWCI
- 16.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.